Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks?
Department of Clinical Neurosciences, Psychiatry and Community Health Sciences, University of Calgary, Calgary, AB, Canada tmprings@ucalgary.ca.
Tamara
T
Pringsheim
Department of Psychiatry and Pharmacy, Dalhouise University, Halifax, NS, Canada.
David
D
Gardner
Department of Community Health Sciences and Psychiatry, University of Calgary.
Scott B
SB
Patten
D000928:Antidepressive Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D003987:Dibenzothiazepines / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000139:chemically induced*; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced*; D000069348:Quetiapine Fumarate; D018570:Risk Assessment; D016896:Treatment Outcome; D015430:Weight Gain
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate